News >

Expert Addresses Abiraterone Versus Docetaxel in Castration-Sensitive Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 05, 2018

Julie Graff, MD

Julie Graff, MD
While pivotal clinical trials, such as CHAARTED, STAMPEDE, and LATITUDE, have demonstrated the efficacy of abiraterone acetate (Zytiga) and/or docetaxel in patients with castration-sensitive prostate cancer, there is still no clear standard of care.

Specifically, the phase III LATITUDE study, showed a 38% reduction in the risk of death with the addition of abiraterone and prednisone to androgen-deprivation therapy (ADT) compared with ADT alone for patients with high-risk metastatic, castration-sensitive prostate cancer. After a median follow-up of 30.4 months, median overall survival was not yet reached with abiraterone versus 34.7 months with ADT alone (HR, 0.62; 95% CI, 0.51-0.76; P <.001).1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication